Sign In
Buy OMCL
$41.89
-0.0200 (-0.0477%)
At Close: Jun 03, 2026
West Pharmaceutical's (WST) Syringe System to Improve Outcome
02:23pm, Thursday, 16'th Jun 2022 Zacks Investment Research
West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.
BD's (BDX) Latest Collaboration to Enhance Patient Care
02:46pm, Wednesday, 15'th Jun 2022 Zacks Investment Research
BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.
Here's Why You Should Hold on to Ecolab (ECL) Stock For Now
02:22pm, Wednesday, 15'th Jun 2022 Zacks Investment Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
CPSI vs. OMCL: Which Stock Is the Better Value Option?
03:40pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
05:03pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
02:18pm, Thursday, 02'nd Jun 2022
Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
10:20am, Wednesday, 01'st Jun 2022 Zacks Investment Research
Style Box ETF report for SLY
Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?
10:20am, Thursday, 26'th May 2022 Zacks Investment Research
Style Box ETF report for IJR
Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?
10:20am, Tuesday, 24'th May 2022 Zacks Investment Research
Style Box ETF report for VIOO
Catalent's (CTLT) Latest Facility Expansion to Boost Capacity
03:25pm, Monday, 23'rd May 2022 Zacks Investment Research
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
03:24pm, Monday, 23'rd May 2022 Zacks Investment Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
02:01pm, Monday, 23'rd May 2022 Zacks Investment Research
Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.
Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now
01:03pm, Friday, 20'th May 2022 Zacks Investment Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.
Catalent's (CTLT) New Launch to Enhance Gene Therapy Development
04:34pm, Thursday, 19'th May 2022 Zacks Investment Research
Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.
NextGen Healthcare (NXGN) Q4 Earnings Miss Mark, Revenues Beat
03:27pm, Wednesday, 18'th May 2022 Zacks Investment Research
NextGen Healthcare's (NXGN) fiscal fourth-quarter earnings reflect strength in its Recurring revenues.
